Molecular Analysis of Mycobacterium tuberculosis Isolated in the North Central Zone of Nigeria
Tóm tắt
Tuberculosis (TB) incidence in Nigeria is high, with a significant burden of TB/Human Immunodeficiency Virus (HIV). Genotyping and drug susceptibility of Mycobacterium tuberculosis Complex (MTBC) are important in order to improve the control of the disease. This study sought to determine drug susceptibility and genetic diversity of MTBC in the country. The sputum samples of 202 patients [133 (65.8%) males/69 (34.2%) females] were collected in the North Central zone of Nigeria and cultured using Lowenstein–Jensen medium. Immunochromatography for the primary identification and Drug Susceptibility Testing (DST) by proportion method, as well as IS6110 typing, regions of difference 1, 4, 9, 12, 702, and 711, and spoligotyping were carried out on the isolates. Following the DST on 202 isolates, 51 (25.2%) showed resistance to at least one drug. Multidrug resistance was observed in 29/202 (14.4%) cases. HIV positivity [37/202 (18.3%) patients] was associated with rifampicin 9/37 (24.3%) resistance (p = 0.012) as well as gender (p = 0.009). Of the 202 isolates, 150 (74.3%) were identified as the Cameroon sublineage, followed by the UgandaI, Haarlem, and West Africa 1 with 18 (8.9%), 10 (5%), and 6 (3%), respectively. The LAM10_CAM was the most prevalent genetic family [128/202 (63.4%)], with the shared international type 61 [111 (55%) isolates] the largest cluster. Gender (p = 0.038) and age (p = 0.015) had significant associations with the LAM10_CAM family but neither with HIV (p = 0.479) nor drug resistance. Rifampicin resistance in TB/HIV coinfected patient is a major concern in the study area. The Mycobacterium africanum lineage showed a marked decrease, and the need to educate females most at risk of TB/HIV coinfection is advocated.
Tài liệu tham khảo
World Health Organization (WHO). Global tuberculosis report 2018. Geneva, Switzerland: World Health Organization; 2018.
Sharma SK, Mohan A. Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest 2006;130;261–72.
Pablos-Méndez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997;102;164–70.
World Health Organization (WHO). Global tuberculosis control: WHO report 2016. Geneva, Switzerland: World Health Organization; 2016.
Galagan JE. Genomic insights into tuberculosis. Nat Rev Genet 2014;15;307–20.
Gagneux S, DeRiemer K, Van T, Kato-Maeda M, de Jong BC, Narayanan S, et al. Variable host–pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006;103;2869–73.
Hirsh AE, Tsolaki AG, DeRiemer K, Feldman MW, Small PM. Stable association between strains of Mycobacterium tuberculosis and their human host populations. Proc Natl Acad Sci USA 2004;101;4871–76.
Ferdinand S, Valétudie G, Sola C, Rastogi N. Data mining of Mycobacterium tuberculosis complex genotyping results using mycobacterial interspersed repetitive units validates the clonal structure of spoligotyping-defined families. Res Microbiol 2004;155;647–54.
Mokrousov I, Jiao WW, Sun GZ, Liu JW, Valcheva V, Li M, et al. Evolution of drug resistance in different sublineages of Mycobacterium tuberculosis Beijing genotype. Antimicrob Agents Chemother 2006;50;2820–3.
Kato-Maeda M, Shanley CA, Ackart D, Jarlsberg LG, Shang S, Obregon-Henao A, et al. Beijing sublineages of Mycobacterium tuberculosis differ in pathogenicity in the guinea pig. Clin Vaccine Immunol 2012;19;1227–37.
Thwaites G, Caws M, Hong Chau TT, D’Sa A, Ngoc Lan NT, Thu Huyen MN, et al. Relationship between Mycobacterium tuberculosis genotype and the clinical phenotype of pulmonary and meningeal tuberculosis. J Clin Microbiol 2008;46;1363–8.
Firdessa R, Berg S, Hailu E, Schelling E, Gumi B, Erenso G, et al. Mycobacterial lineages causing pulmonary and extrapulmonary tuberculosis, Ethiopia. Emerg Infect Dis 2013;19;460–3.
Kato-Maeda M, Metcalfe JZ, Flores L. Genotyping of Mycobacterium tuberculosis: application in epidemiologic studies. Future Microbiol 2011;6;203–16.
Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 2007;7;328–37.
Huard RC, de Oliveira Lazzarini LC, Butler WR, van Soolingen D, Ho JL. PCR-based method to differentiate the subspecies of the Mycobacterium tuberculosis complex on the basis of genomic deletions. J Clin Microbiol 2003;41;1637–50.
Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüsch-Gerdes S, Willery E, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 2006;44;4498–510.
Aminian M, Shabbeer A, Bennett KP. A conformal Bayesian network for classification of Mycobacterium tuberculosis complex lineages. BMC Bioinformatics 2010;11;S4.
Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997;35;907–14.
Brudey K, Driscoll JR, Rigouts L, Prodinger WM, Gori A, Al-Hajoj SA, et al. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol 2006;6;23.
Wang HY, Lu JJ, Chang CY, Chou WP, Hsieh JC, Lin CR, et al. Development of a high sensitivity TaqMan-based PCR assay for the specific detection of Mycobacterium tuberculosis complex in both pulmonary and extrapulmonary specimens. Sci Rep 2019;9;113.
McEvoy CRE, Falmer AA, Gey van Pittius NC, Victor TC, van Helden PD, Warren RM. The role of IS6110 in the evolution of Mycobacterium tuberculosis. Tuberculosis (Edinb) 2007;87; 393–404.
Thierry D, Cave MD, Eisenach KD, Crawford JT, Bates JH, Gicquel B, et al. IS6110, an IS-like element of Mycobacterium tuberculosis complex. Nucleic Acids Res 1990;18;188.
van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993;31;406–9.
Uddin MKM, Ahmed M, Islam MR, Rahman A, Khatun R, Hossain MA, et al. Molecular characterization and drug susceptibility profile of Mycobacterium tuberculosis isolates from Northeast Bangladesh. Infect Genet Evol 2018;65;136–43.
Adesokan HK, Streicher EM, van Helden PD, Warren RM, Cadmus SIB. Genetic diversity of Mycobacterium tuberculosis complex strains isolated from livestock workers and cattle in Nigeria. PLoS One 2019;14;e0211637.
Luo D, Chen Q, Xiong G, Peng Y, Liu T, Chen X, et al. Prevalence and molecular characterization of multidrug-resistant M. tuberculosis in Jiangxi province, China. Sci Rep 2019;9;7315.
Brosch R, Gordon SV, Marmiesse M, Brodin P, Buchrieser C, Eiglmeier K, et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA 2002;99;3684–9.
de Jong BC, Antonio M, Gagneux S. Mycobacterium africanum—review of an important cause of human tuberculosis in West Africa. PLoS Negl Trop Dis 2010;4;e744.
Warren RM, Gey van Pittius NC, Barnard M, Hesseling A, Engelke E, de Kock M, et al. Differentiation of Mycobacterium tuberculosis complex by PCR amplification of genomic regions of difference. Int J Tuberc Lung Dis 2006;10;818–22.
Weniger T, Krawczyk J, Supply P, Niemann S, Harmsen D. MIRU-VNTRplus: a web tool for polyphasic genotyping of Mycobacterium tuberculosis complex bacteria. Nucleic Acids Res 2010;38;W326–W31.
Lawson L, Yassin MA, Abdurrahman ST, Parry CM, Dacombe R, Sogaolu OM, et al. Resistance to first-line tuberculosis drugs in three cities of Nigeria. Trop Med Int Health 2011;16;974–80.
Thumamo BP, Asuquo AE, Abia-Bassey LN, Lawson L, Hill V, Zozio T, et al. Molecular epidemiology and genetic diversity of Mycobacterium tuberculosis complex in the Cross River State, Nigeria. Infect Genet Evol 2012;12;671–7.
Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009;373;1861–73.
Onyedum CC, Alobu I, Ukwaja KN. Prevalence of drug-resistant tuberculosis in Nigeria: a systematic review and meta-analysis. PLoS One 2017;12;e0180996.
Kooffreh ME, Offor JB, Ekerette EE, Udom UI. Prevalence of tuberculosis in Calabar, Nigeria: a case study of patients attending the outpatients Department of Dr. Lawrence Henshaw Memorial Hospital, Calabar. Saudi J Health Sci 2016;5;130–3.
Adetunji SO, Donbraye E, Ekong MJ, Adetunji BI. Rifampicin-resistant tuberculosis among known HIV-infected patients in Oyo state, Nigeria. J Immunoass Immunoch 2019;40;289–99.
Dinic L, Akande P, Idigbe EO, Ani A, Onwujekwe D, Agbaji O, et al. Genetic determinants of drug-resistant tuberculosis among HIV infected patients in Nigeria. J Clin Microbiol 2012;50;2905–9.
Rijal KR, Ghimire P, Rijal B, Bam DS. The pattern of anti-tuberculosis drug resistance in pulmonary tuberculosis patients. J Inst Med 2005;27;26–8.
Nasiri MJ, Haeili M, Ghazi M, Goudarzi H, Pormohammad A, Imani Fooladi AA, et al. New insights in to the intrinsic and acquired drug resistance mechanisms in mycobacteria. Front Microbiol 2017;8;681.
da Silveira Paro Pedro H, Nardi SMT, Pereira MIF, Oliveira RS, Suffys PN, Gomes HM, et al. Clinical and epidemiological profiles of individuals with drug-resistant tuberculosis. Mem Inst Oswaldo Cruz 2015;110;235–41.
World Health Organization (WHO). Stop TB partnership: 2010/2011 Tuberculosis Global Facts; 2010. Available from: http://www.who.int/tb/publications/2010/factsheet_tb_2010.pdf.
Demile B, Zenebu A, Shewaye H, Xia S, Guadie A. Risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia. BMC Infect Dis 2018;18;249.
Pokam BT, Asuquo AE, Abia-Bassey LN, Idasa MB, Umoh NO, Eko FO, et al. Multidrug resistance and demography of newly diagnosed tuberculosis patients in Cross River State, Nigeria. Int J Mycobacteriol 2013;2;89–93.
Artiom J, Evelina L. Social determinants of drug-susceptible and drug resistant tuberculosis. Eur Respir J 2016;48;PA2749.
Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006;61;158–63.
Ullah I, Javaid A, Tahir Z, Ullah O, Shah AA, Hasan F, et al. Pattern of drug resistance and risk factors associated with development of drug resistant Mycobacterium tuberculosis in Pakistan. PLoS One 2016;11;e0147529.
Ejaz M, Siddiqui AR, Rafiq Y, Malik F, Channa A, Mangi R, et al. Prevalence of multi-drug resistant tuberculosis in Karachi, Pakistan: identification of at risk groups. Trans R Soc Trop Med Hyg 2010;104;511–17.
Lomtadze N, Aspindzelashvili R, Janjgava M, Mirtskhulava V, Wright A, Blumberg HM, et al. Prevalence and risk factors for multidrug-resistant tuberculosis in the Republic of Georgia: a population-based study. Int J Tuberc Lung Dis 2009;13;68–73.
Mor Z, Goldblatt D, Kaidar-Shwartz H, Cedar N, Rorman E, Chemtob D. Drug-resistant tuberculosis in Israel: risk factors and treatment outcomes. Int J Tuberc Lung Dis 2014;18;1195–201.
Lawson L, Zhang J, Gomgnimbou MK, Abdurrahman ST, Le Moullec S, Mohamed F, et al. A molecular epidemiological and genetic diversity study of tuberculosis in Ibadan, Nnewi and Abuja, Nigeria. PLoS One 2012;7;e38409.
Uzoewulu GN, Lawson L, Nnanna IS, Rastogi N, Goyal M. Genetic diversity of Mycobacterium tuberculosis complex strains isolated from patients with pulmonary tuberculosis in Anambra State, Nigeria. Int J Mycobacteriol 2016;5;74–9.
Ani A, Bruvik T, Okoh Y, Agaba P, Agbaji O, Idoko J, et al. Genetic diversity of Mycobacterium tuberculosis complex in Jos, Nigeria. BMC Infect Dis 2010;10;189.
Kamgue Sidze L, Mouafo Tekwu E, Kuaban C, Assam Assam J, Tedom J, Niemann S, et al. Estimates of genetic variability of Mycobacterium tuberculosis complex and its association with drug resistance in Cameroon. Adv Infect Dis 2013;3;55–9.
Niobe-Eyangoh SN, Kuaban C, Sorlin P, Cunin P, Thonnon J, Sola C, et al. Genetic biodiversity of Mycobacterium tuberculosis complex strains from patients with pulmonary tuberculosis in Cameroon. J Clin Microbiol 2003;41;2547–53.
Godreuil S, Torrea G, Terru D, Chevenet F, Diagbouga S, Supply P, et al. First molecular epidemiology study of Mycobacterium tuberculosis in Burkina Faso. J Clin Microbiol 2007;45;921–7.
Affolabi D, Anyo G, Faïhun F, Sanoussi N, Shamputa IC, Rigouts L, et al. First molecular epidemiological study of tuberculosis in Benin. Int J Tuberc Lung Dis 2009;13;317–22.
Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, Jacobson KR, Victor TC, et al. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet 2013;45;1183–9.
Zhang H, Li D, Zhao L, Fleming J, Lin N, Wang T, et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet 2013;45;1255–60.
Osório NS, Rodrigues F, Gagneux S, Pedrosa J, Pinto-Carbó M, Castro AG, et al. Evidence for diversifying selection in a set of Mycobacterium tuberculosis genes in response to antibiotic- and nonantibiotic-related pressure. Mol Biol Evol 2013;30;1326–36.
Coscolla M, Gagneux S. Consequences of genomic diversity in Mycobacterium tuberculosis. Semin Immunol 2014;26;431–44.
Pokam BT, Asuquo AE. Acid-fast bacilli other than mycobacteria in tuberculosis patients receiving directly observed therapy short course in Cross River State, Nigeria. Tuberc Res Treat 2012;2012;1–4.